Loading
An ADC payload neutraliser is an antibody given alongside an ADC that mops up the poison once it leaks into the bloodstream, so the ADC can hit the tumour with fewer side effects.
Free payload released from ADCs in circulation drives much of their toxicity (neuropathy, rash, hyperglycaemia with MMAE; neutropenia with SN-38). A neutralising antibody with high affinity for the free payload but not the conjugated form could widen the therapeutic index without changing the ADC. Generate Biomedicines' GB-4362, an AI-designed MMAE neutraliser, entered the clinic in 2026 with FDA Fast Track designation for enfortumab vedotin-induced toxicity in urothelial cancer.
Antibody binds the released small-molecule payload in plasma, preventing uptake by normal tissue; conjugated payload on the ADC remains unaffected.
Query for this technology: (TITLE:"ADC payload neutralisers" OR ABSTRACT:"ADC payload neutralisers") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ADC payload neutralisers, not a curated reading list.
Shares De novo designed protein binders, AI-driven drug & target discovery and the tag frontier.
Shares Acquired resistance to every therapy, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Bladder & urothelial cancer and the tag frontier.
Shares Bladder & urothelial cancer and the tag frontier.
Shares Acquired resistance to every therapy, Bladder & urothelial cancer, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Antibody-drug conjugate (ADC) and the tag frontier.
Shares Antibody-drug conjugate (ADC) and the tag frontier.
Shares AI-driven drug & target discovery and the tag frontier.